150 000 occur in the United States. 1, 2 Thirty-five to 55% of colorectal cancer patients will develop liver metastases, which is often the only site of distant disease. [3] [4] [5] Complete resection of colorectal liver metastases (CRLM) is the only potentially curative treatment option and is associated with prolonged survival. 6, 7 Unfortunately, up to 85% of patients with CRLM are unresectable at presentation. [8] [9] [10] With current systemic chemotherapy options, a small minority of these patients will have sufficient response to allow complete resection and clearance of disease. 7, 11, 12 Hepatic artery infusion (HAI) chemotherapy allows precise delivery of high-dose regional hepatic chemotherapy. Taking advantage of the anatomic dependence of metastatic liver tumors on hepatic arterial blood supply, HAI chemotherapy effectively delivers a high-concentration of drug to the liver disease, and minimizes any adverse effect on normal parenchyma. 9,13,14 5-fluoro-2-deoxyuridine (FUDR) is a particularly suitable chemotherapeutic drug for intrahepatic delivery, with a high first-pass hepatic extraction of 94-99%. 15 The limited systemic exposure of HAI FUDR provides the opportunity for combinatory regimens with systemic agents, which has been demonstrated to be safe and effective, even in patients with multiple prior lines of therapy. 16 With conventional systemic (SYS) chemotherapy alone, the median survival for patients with unresectable CRLM is approximately 30 months. [17] [18] [19] [20] [21] [22] [23] [24] In patients whose tumors are RAS-wild-type, a higher median survival of over three years has been reported. [25] [26] [27] [28] Conversion to complete resection with SYS chemotherapy has been
reported, but conversion rates are low, ranging from 13% to 27%. 6, 7, 12, 29 Furthermore, reports of conversion are methodologically flawed due to lacking or vague definitions of resectability.
Prior randomized trials of combination HAI and SYS chemotherapy have demonstrated promising results with response rates of 55-88% with nearly half of patients converting to complete resection. 16, [30] [31] [32] In our initial report of a phase II trial evaluating patients with unresectable CRLM, 47% were converted to resection after treatment with HAI and SYS chemotherapy. The present study represents the long-term results of this trial and includes an expansion cohort not originally reported. 33 We have also included an analysis of outcomes stratified by tumor KRAS mutational status. The primary objective of this study was to assess conversion to resection and to evaluate the long-term survival and curative potential of patients with unresectable CRLM in this expanded phase II of HAI FUDR in combination with best SYS chemotherapy.
| METHODS
This is a prospective, non-randomized, single-institution phase II trial (Registration #NCT00492999) approved by the MSKCC institutional review board. Patients presenting with unresectable CRLM were evaluated for trial eligibility from July 2007 to July 2012. All patients had histologically confirmed colorectal carcinoma and no evidence of extrahepatic metastatic disease on cross-sectional imaging performed within 6 weeks of trial enrollment. This protocol involved a two-step registration process. Patients were registered to Step 1 prior to pump placement, and then eligible patients were registered to Step 2 after pump placement. Only patients registered to both Step 1 and Step 2 were included. As previously reported, irresectability was determined by two hepatobiliary surgeons and one radiologist and primarily defined as technical irresectability (a margin-negative resection would require resection of all three hepatic veins, both portal veins, or the retrohepatic vena cava, or a resection would result in <2 adequately perfused and drained liver segments); a small group of patients were also defined as biologically irresectable due to burden of disease (>6 metastases in a single lobe, with one lesion ≥5 cm; or ≥6 bilobar metastases) and also included. 33 The definition of irresectability used in this study was the result of the consensus among our institution's medical and surgical oncologists. 34, 35 Patients were excluded from this study if they had prior liver resection or radiation, any evidence of end organ insufficiency, or Karnofsky performance score <60%. Prior to treatment initiation, all patients underwent detailed cross-sectional imaging, HAI pump insertion, and tissue biopsy, as detailed in the original trial publication. 33 All patients were assigned to received HAI FUDR in combination with best SYS chemotherapy (either oxaliplatin/irinotecan or 5-FU/ leucovorin/irinotecan) as determined by their prior chemotherapy history, in addition to Bevacizumab (Bev). 33 Bev was given to the first 24 patients but subsequently discontinued due to unexpected biliary toxicity (reported below); after IRB authorization and protocol amendment, the subsequent 40 patients did not received Bev treatment. Toxicities and complications were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 3.0. 36 Biliary toxicity was graded as previously reported. 30, 37 Patients were evaluated at least every 2 weeks during treatment with physical examination, complete blood count, complete metabolic panel, and carcinoembryonic antigen. Molecular genotyping for the KRAS mutational status was performed, as previously described. 38 Mutations in KRAS (codons 12 and 13) were identified using the iPLEX assay (Sequenom Inc, San Diego, CA).
The primary endpoint evaluated in this study was conversion to complete gross resection. Patients with a sufficient response to treatment were explored for potential resection. Treatment response was evaluated using World Health Organization criteria. 39 Resectability was re-assessed after the 4th cycle of therapy and then every two cycles after that. Surgical strategies for resection included ablation and 2-stage resections. All attempts were made to resect all sites of prior disease; however, sites of radiographic complete response that were not visualized at surgery were not required to be resected. Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic progression-free survival (HPFS), tumor response rate, and treatment-related toxicities and complications.
The initial study was powered using the historical conversion rate with systemic chemotherapy at the time of trial design of 15%. In order to detect at least a doubling of the historical rate with 90% power, a sample size of 49 patients was determined. Fifteen patients not reported in the original publication were added as an expansion cohort to further clarify and confirm our initial findings. We conducted a landmark analysis using resection at 12 months as a pre-defined landmark time, in order to examine the effect of resection on OS using Kaplan-Meier methods. 40 The landmark analysis attempts to account for the inherent bias in comparing patients with favorable responses to those with less favorable responses. Patients who had less than 12-month follow-up were excluded from landmark analysis and patients resected after 12 months were counted in the non-resection group.
All P-values were based on 2-tailed statistical analysis and P < 0.05 was considered statistically significant. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC) and R (13.0).
3 | RESULTS
| Patient characteristics
A total of 117 patients with unresectable CRLM were reviewed for study eligibility between July 2007 and July 2012. Fifty-three patients were excluded from the study (thirty-four had extrahepatic disease; one had extrahepatic perfusion after hepatic pump placement; eight were resected at the time of pump placement; two had significant comorbidities; four developed post-operative complications; one had FUDR started early; one had no evidence of malignancy on pathology; one patient declined study enrollment; and one was enrolled in a different study). Sixty-four eligible patients were enrolled. All but three patients were defined as technically 
| Toxicity
Grade 3/4 diarrhea occurred in 13% of patients and neutropenia occurred in 2% (Table 2 ). Elevated liver function tests was the most common toxicity with 20% of patients showing an increase in liver enzymes.
Patients who received Bev with HAI and SYS regimens had unexpectedly significant biliary toxicity, with three of 24 patients (13%) requiring biliary stenting. Among the remaining 40 patients treated without Bev, one (2.5%) required biliary stenting.
| Response and conversion to resection
The overall response rate (RR) was 73%, with 47 patients having a complete or partial response (1 CR, 46 PR). Seventeen patients had stable disease (SD), and no patients had progression of disease. 
| Long-term follow up and survival
The median follow-up for surviving patients was 81 months (58-114 months). There were 17 patients alive at last follow-up.
Nine of these patients were NED, of whom eight underwent resection and one had a durable CR and never had surgery for liver metastases. (Table 3) . Age, prior chemotherapy, and conversion to resection were associated with PFS on univariate analysis. On multivariate analysis, only age and conversion to resection remained a significant predictor of PFS (Table 3) . 
| Landmark analysis

| DISCUSSION
This study reached its primary endpoint with a conversion rate to complete resection of well over the anticipated doubling of the historical rate. Thirty-three of the 64 patients (52%) presenting with unresectable CRLM had sufficient radiologic response after treatment with combination HAI and SYS chemotherapy to undergo resection, demonstrating a significantly promising rate of conversion. Despite a high rate of prior treatment, the overall RR was 73% and median OS of all patients was 38 months with a significant difference in OS between those who were able to undergo resection and those who were not.
Studies on the use of SYS chemotherapy alone in patients with unresectable CRLM have reported a much lower conversion rate to resection, ranging from 13% to 38%. 6, 12, 29, [41] [42] [43] While these rates have improved since the initiation of our study, very few studies have reported results comparable to our 52% conversion to resection rate.
As resection is the only potentially curative treatment option, this remains a critical outcome to consider. In these prior studies, | 639 resectability was often not clearly defined and thus, it is difficult to determine how truly unresectable these patients were at presentation.
In comparison, the criteria for irresectability in our study were prospectively designed and defined at the initiation of this study This trial also demonstrated significantly longer survival for patients who were converted to resection than the previously reported range of 35.2-48.4 months for converted patients from SYS chemotherapy alone. [44] [45] [46] Although our study patients all presented
with an extensive burden of disease, the predicted 5-year OS for patients who were able to convert to complete resection was 63%, which is similar to the rate seen in patients with initially resectable disease, and higher than that demonstrated among patients converted to resection with SYS chemotherapy alone. 12, 29 This may represent an additional survival benefit from improved targeted local disease control with the addition of HAI chemotherapy. 47 These findings strongly support the use of combination HAI and SYS chemotherapy as a therapeutic strategy to improve the rate of conversion to resection and optimize long-term disease control. As SYS chemotherapy regimens continue to evolve, additional studies are needed to evaluate the benefit of the potential benefit of the addition of HAI chemotherapy in combination with these novel treatment protocols.
Interestingly, when we evaluated the KRAS mutational status of study patients, we identified an improved RR to the study regimen for patients with KRAS WT tumors compared with KRAS MUT (68% vs 56%, P = 0.009). While KRAS has been demonstrated as a predictive marker of response of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer, it is unclear whether if this also applies to other chemotherapy regimens. 48, 49 We did not find a significant association in our study between KRAS mutational status and conversion to resection or survival outcomes, which is potentially due to the relatively small size of the study population compared to prior studies and as this study was not powered to perform this subgroup analysis. 50 disease and failure of disease control on prior chemotherapy treatments.
The main limitation of this study is the rigorous patient selection process that resulted in patients with good functional status, which may not be an accurate representation of the overall population of patients with CRLM. In addition, while criteria for irresectability were prospectively defined, these are not standardized and may reflect an institutional bias. However, as a prospective trial, this study demonstrates the promise that combination HAI and SYS chemotherapy holds in dramatically improving outcomes for patients presenting with unresectable CRLM with otherwise limited therapeutic options.
The current availability of HAI chemotherapy is also limited to certain centers worldwide; however, we hope the high rates of conversion to resection and the survival benefits of HAI and SYS chemotherapy demonstrated in the present study will encourage more centers to incorporate this combinatorial regimen into their practice.
| CONCLUSIONS
Combination HAI and SYS chemotherapy is an effective treatment regimen in patients with unresectable CRLM with a high rate of conversion to resection and long-term survival. Despite presenting with an advanced high burden of disease and failure on prior conventional therapies, prolonged disease-free survival and potential cure can still be achieved. Large-scale, prospective, randomized trials investigating this combinatory therapy are indicated to further define its long-term benefits and delineate the appropriate criteria for patient selection.
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